Latest news
CILcare expands its Scientific Advisory Board to accelerate its research projects in synaptopathy, an early marker of age-related diseases
Montpellier, France, March 13 2023 – CILcare, a company specialized in the R&D of novel therapies for hearing disorders, has the immense pleasure of welcoming four renown researchers in the field of hearing to its Scientific Advisory Board (SAB): Keith Darrow,...
Join CILcare at ARO’s 2023 Midwinter Meeting
CILcare's team will be in Orlando, FL, to take part in ARO's Midwinter Meeting on February 11-15, 2023. The Association for Research in Otolaryngology (ARO) is an international hearing and vestibular research society that gathers universities, medical centers,...
Check out Celia Belline’s & Peter Markham’s interview in “This Week in Hearing”
In this interview with Hearing Health Matters, Celia and Peter recount their successful strategic collaboration, marking its fifth anniversary, and their recent award for their innovative preclinical auditory services in the third annual Hearing Technology Innovator...
CILcare, a catalyzer for therapeutic development in ear and age-related disorders
CILcare, a catalyzer for therapeutic development in ear and age-related disorders
CILcare is a Smart R&D Platform specialized in ear and age-related disorders. We offer preclinical and clinical services to accelerate the development of innovative products for hearing loss, tinnitus, otic and age-related disorders.
Because research & development in hearing and ageing is as fascinating as it is complex, preclinical studies require perfectly accurate and reproducible measures using state-of-the-art technology in acoustics and electrophysiology. CILcare’s core values lie in our validated and highly robust animal models, enabling us to deliver consistent and valid results.
Drawing from an extensive industrial background, we guide our partners from target identification to IND and further, and work closely together to advance auditory research and reach a common goal: serve patient population who need our help the most.
Testimonials

Pharma / Biotech

Medtech

Nutraceutical

Veterinary
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect 2.5 billion people globally by 2050 according to the WHO. In 2019, 1.6 billion people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 1 trillion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.
CILcare proposes services to develop innovative solutions for hearing loss, tinnitus, otitis, and ototoxicity

Drugs to treat Hearing Loss and Tinnitus

Drugs and Medical Devices to treat Otitis

Medications safe for the ear (absence of ototoxicity)

Regenerative Therapies: Gene and Cell Therapies
